ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma (pages 3445–3456)
Antoine Italiano, Armelle Laurand, Audrey Laroche, Paolo Casali, Roberta Sanfilippo, Axel Le Cesne, Ian Judson, Jean-Yves Blay, Isabelle Ray-Coquard, Binh Bui, Jean-Michel Coindre, Antonio Nieto, Juan-Carlos Tercero, Jose Jimeno, Jacques Robert and Philippe Pourquier
Version of Record online: 1 FEB 2011 | DOI: 10.1002/cncr.25925
The authors investigated biomarkers that indicated potential clinical benefit from trabectedin, a drug that has been approved in Europe for the treatment of patients with advanced soft-tissue sarcoma (STS). The results suggested that the status of the genes excision repair cross-complementation group 5 (ERCC5), ERCC1, and breast cancer 1 (BRCA1) represents a potential DNA repair signature that could be used for the prediction of clinical response to trabectedin in patients with STS.